MXCT Logo

MaxCyte, Inc. (MXCT) 

NASDAQ
Market Cap
$400.92M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
143 of 776
Rank in Industry
19 of 100

Largest Insider Buys in Sector

MXCT Stock Price History Chart

MXCT Stock Performance

About MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. …

Insider Activity of MaxCyte, Inc.

Over the last 12 months, insiders at MaxCyte, Inc. have bought $489,066 and sold $1.93M worth of MaxCyte, Inc. stock.

On average, over the past 5 years, insiders at MaxCyte, Inc. have bought $12.02M and sold $20.42M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Masoud Maher (President and CEO) — $489,066.

The last purchase of 70,443 shares for transaction amount of $345,241 was made by Masoud Maher (President and CEO) on 2024‑06‑10.

List of Insider Buy and Sell Transactions, MaxCyte, Inc.

2024-11-01Saledirector
47,689
0.0448%
$3.72$177,403-0.27%
2024-10-28Saledirector
3,000
0.0028%
$3.72$11,1660.00%
2024-10-02Saledirector
21,607
0.0196%
$3.71$80,162+0.67%
2024-10-01Saledirector
26,082
0.0241%
$3.78$98,590+1.62%
2024-09-26Saledirector
3,000
0.0028%
$3.82$11,4600.00%
2024-09-04Saledirector
29,767
0.0288%
$3.97$118,175-2.31%
2024-09-03Saledirector
17,922
0.0171%
$4.10$73,480-6.36%
2024-08-26Saledirector
3,000
0.0028%
$4.28$12,840-10.62%
2024-08-02SaleEVP, GLOBAL SALES
17,857
0.017%
$4.36$77,874-9.38%
2024-08-01SaleEVP, GLOBAL SALES
15,476
0.0147%
$4.54$70,261-13.35%
2024-07-26Saledirector
3,000
0.0028%
$4.75$14,238-17.33%
2024-07-09SaleEVP, GLOBAL SALES
13,531
0.0131%
$4.03$54,5840.00%
2024-07-08SaleEVP, GLOBAL SALES
19,802
0.0192%
$4.03$79,7820.00%
2024-06-27Saledirector
10,000
0.0096%
$3.99$39,9000.00%
2024-06-20SaleEVP, GLOBAL SALES
33,333
0.0279%
$4.09$136,465-2.16%
2024-06-10PurchasePresident and CEO
70,443
0.0666%
$4.90$345,241-17.34%
2024-06-07PurchasePresident and CEO
29,557
0.0283%
$4.87$143,824-15.64%
2024-03-26Saledirector
5,000
0.0049%
$4.41$22,025-5.05%
2024-01-26Saledirector
5,000
0.0049%
$5.12$25,585-16.12%
2023-12-26Saledirector
5,000
0.0048%
$4.53$22,650-3.74%

Insider Historical Profitability

<0.0001%
Masoud MaherPresident and CEO
100000
0.0952%
$3.8223
Casdin Partners Master Fund, L.P.10 percent owner
10000000
9.5157%
$3.8212<0.0001%
DOUGLAS RICHARDdirector
100000
0.0952%
$3.8220<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$30.29M6.97.23M-1.52%-$468,496.47<0.01
Cadian Capital Management LP$27.49M6.266.56M+16.22%+$3.84M0.98
Millennium Management LLC$25.86M5.896.17M+23.12%+$4.86M0.02
The Vanguard Group$22.4M5.15.35M+1.23%+$272,366.76<0.0001
Vitruvian Partners$21.13M4.815.04M0%+$06.7
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.